What is Glutathione?
A small three-amino-acid molecule the body makes, mostly in the liver, that cells use in their own antioxidant chemistry.
US legal status
Open question
Whether the FDA will add glutathione to the 503A bulks list, or leave it off, is not settled. In 2022 FDA staff recommended against listing it and the FDA's advisory committee voted 8 to 5, with 1 abstention, in favor; we found no final rule.
Changes
What the human evidence looks like
What programs claim, and what has been studied
Safety facts
Reports to the FDA
- The FDA's adverse event database (FAERS, updated October 28, 2026) holds about 2,158 reports that list glutathione among the products taken; top terms include nausea, abnormal liver function and fever. The reports are not checked, glutathione is often one of several drugs taken, and they do not show cause.16
- FAERS data to October 28, 2026 hold 2,158 reports that name glutathione among the products taken, 1,728 of them marked serious. By country: China 862, US 666, Italy 61, Japan 48, Canada 45.34
- Top terms in all FAERS reports to October 28, 2026: nausea 143, off-label use 139, platelet count decreased 130, abnormal liver function 128, fatigue 126, fever 118, anemia 116, headache 111, diarrhea 108, low white cell count 99. Many blood-count terms likely reflect use alongside cancer drugs, since glutathione is often listed with other drugs; the reports do not show cause.34
- Top terms in the 666 US FAERS reports to October 28, 2026: fatigue 96, headache 81, nausea 68, pain 51, dizziness 46, joint pain 44, shortness of breath 44, insomnia 40, anxiety 38, diarrhea 38.34
- FAERS reports by year, all countries: 2016, 148; 2017, 96; 2018, 120; 2019, 129; 2020, 183; 2021, 219; 2022, 217; 2023, 186; 2024, 191; 2025, 195; 2026, 183 (to October 28).34
- FAERS holds 56 US reports for 2026 (to October 28); the top terms are off-label use (6), drug ineffective (5) and headache (5). Fever is not among the top terms, so the cluster of at least 30 patients the FDA described does not show in this public data.34
What the FDA has said
- At its 2022 advisory committee meeting, the FDA named anaphylaxis, hypersensitivity and liver toxicity with IV use, and bronchoconstriction, wheezing and coughing up blood (hemoptysis) when inhaled. It had no studies of long-term IV use, and raised a possible concern about sun-induced skin cancer with skin lightening.11
- The FDA warns that unapproved skin-lightening injections may contain unknown ingredients or contaminants, and that unsafe injection practices can spread infection.1718
In studies and reviews
No data
- We found no data on pregnancy or breastfeeding, on long-term injected use, or on children. A member of the FDA's advisory committee cited missing reproductive and developmental toxicology data.11
Product quality
- The FDA has reported high bacterial endotoxin in compounded glutathione injections: 8 patients in 2019 and at least 30 in 2026, some hospitalized. Reactions included fever, chills, low blood pressure, trouble breathing and sepsis-like symptoms.12
- Victory Medical Center Pharmacy in Austin recalled 3 lots (1980571, 1981940, 1984345) of 200 mg/mL "multi-dose" vials shipped to Texas, Florida and New York, announced and posted on August 5, 2026, with reports of fever, chills, severe headache, nausea, vomiting, fast heart rate, blood pressure changes, body aches and injection-site reactions. Optimal Balance Pharmacy in Houston recalled 1 lot (LG342009076) of 200 mg/mL 30 mL vials shipped to 14 states (AZ, CO, FL, IL, LA, MI, NY, NV, OK, PA, TX, UT, VT, WA), dated August 19 by the company and posted by the FDA on August 20, 2026, with reports of fever, chills, severe headache, nausea, vomiting, pain and allergic-type symptoms. Both said "pharmacy testing identified elevated bacterial endotoxin levels".34
- The FDA named the root cause: powder of dietary supplement grade used to make injections. It says such ingredients are "not suitable for making injectable drugs".2
- In its notice of August 27, 2026, the FDA said the glutathione was given by IV, alone or with other ingredients, and compounded by different pharmacies that all got lot #229536 from Medisca Inc., labeled dietary supplement grade. Reactions included fever, chills, pain, dizziness, signs of shock and sepsis-like symptoms, and some patients were hospitalized; Medisca told the FDA on August 20, 2026 that it had warned its US customers, and the FDA "continues to receive reports" and is investigating.2
Compounded glutathione is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.
You can report a side effect to the FDA through MedWatch.
What a trustworthy program shows
- 1.FDA, "FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables" (2019)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 2.FDA, "FDA reminds compounders not to use dietary supplement grade glutathione in injectables" (Aug 27 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 3.FDA recall notice, Victory Medical Center Pharmacy, compounded glutathione 200 mg/mL (Aug 5 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 4.FDA recall notice, Optimal Balance Pharmacy, compounded glutathione 200 mg/mL (Aug 19 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 5.FDA, "Bulk Drug Substances Used in Compounding Under Section 503A" (current 05/14/2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 6.FDA, 503A nominated bulk substances categories list (updated May 14 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 7.FDA, 503B nominated bulk substances categories (Mar 21 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 8.FDA, 503B Bulk Drug Substances List (current 05/16/2024)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 9.Federal Register 2026-22192, HHS interim enforcement discretion, 503A peptides (Oct 30 2026)Tier 1: regulator or registergovinfo.govread Nov 16, 2026↩
- 10.RAPS, "HHS will permit compounding of six peptides ahead of formal rulemaking" (Oct 29 2026)Tier 3: reference, law firm or pressraps.orgread Nov 16, 2026↩
- 11.FDA, PCAC June 8 2022 meeting transcriptTier 1: regulator or registerfda.govread Nov 16, 2026↩
- 12.FDA, PCAC June 8 2022 meeting questionsTier 1: regulator or registerfda.govread Nov 16, 2026↩
- 13.FDA, PCAC June 2022 conflict-of-interest waiver memo (glutathione background)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 14.A4PC, "PCAC recommends glutathione for bulks list" (June 2022)Tier 4: lead onlya4pc.orgread Nov 16, 2026
- 15.openFDA Drugs@FDA query, active ingredient glutathioneTier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 16.openFDA FAERS query, medicinalproduct glutathione (last updated 2026-10-28)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 17.FDA consumer update (Japanese translation), injectable skin lightening productsTier 1: regulator or registerfda.govread Nov 16, 2026↩
- 18.AmSpa repost of FDA consumer update on injectable skin lightening (Sept 2015)Tier 3: reference, law firm or pressamericanmedspa.orgread Nov 16, 2026↩
- 19.USP35–NF30 "Glutathione" monograph (mirror)Tier 3: reference, law firm or pressdrugfuture.comread Nov 16, 2026↩
- 20.APC brief, Dietary Supplement Monograph (May 17 2021)Tier 3: reference, law firm or pressold.a4pc.orgread Nov 16, 2026↩
- 21.USADA, "IV Infusions: Explanatory Note" (modified Jul 14 2026)Tier 1: regulator or registerusada.orgread Nov 16, 2026↩
- 22.Alzahrani et al., "Glutathione supplementation for skin lightening: narrative review", Cureus 2025Tier 2: peer-reviewed or trial registrypmc.ncbi.nlm.nih.govread Nov 16, 2026↩
- 23.Khanna et al., "Systematic review of topical glutathione in dermatology", JCAD 2025Tier 2: peer-reviewed or trial registryjcadonline.comread Nov 16, 2026↩
- 24.Cochrane: Ciofu et al., "Antioxidant supplementation for lung disease in cystic fibrosis" (2019)Tier 2: peer-reviewed or trial registrycochrane.orgread Nov 16, 2026↩
- 25.Hauser et al., "Randomized, double-blind, pilot evaluation of IV glutathione in Parkinson's disease", Mov Disord 2009 (PMID 19230029, via Europe PMC)Tier 2: peer-reviewed or trial registryebi.ac.ukread Nov 16, 2026↩
- 26.Richie et al., "RCT of oral glutathione supplementation on body stores", Eur J Nutr 2015Tier 2: peer-reviewed or trial registrypure.psu.eduread Nov 16, 2026↩
- 27.Heally, glutathione injections pageTier 4: lead onlygetheally.comread Nov 16, 2026↩
- 28.Invigor Medical, buy glutathione pageTier 4: lead onlytryinvigor.comread Nov 16, 2026↩
- 29.Wisp, glutathione injections pageTier 4: lead onlyhellowisp.comread Nov 16, 2026↩
- 30.Eden, glutathione treatment pageTier 4: lead onlyeden.healthread Nov 16, 2026↩
- 31.Eden press release, PR Newswire (May 20 2025)Tier 4: lead onlyprnewswire.comread Nov 16, 2026
- 32.TrimRx blog, "Best Glutathione Injection Providers in 2026"Tier 4: lead onlytrimrx.comread Nov 16, 2026
- 33.NutraIngredients-USA, Kyowa Hakko GRAS self-affirmation for Setria (2018)Tier 4: lead onlynutraingredients-usa.comread Nov 16, 2026↩
- 34.openFDA FAERS counts naming glutathione: total, seriousness, reactions, country, year (data to Oct 28, 2026)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 35.ClinicalTrials.gov API v2, studies with glutathione as an intervention (277 records)Tier 1: regulator or registerclinicaltrials.govread Nov 16, 2026
- 36.PubMed eutils counts for glutathione (total, humans, animals only, RCTs)Tier 1: regulator or registereutils.ncbi.nlm.nih.govread Nov 16, 2026
- 37.Witschi A et al. The systemic availability of oral glutathione. Eur J Clin Pharmacol 1992;43(6):667-9 (PMID 1362956)Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 38.Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med 2011;17(9):827-33 (PMID 21875351)Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 39.Sinha R et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Eur J Clin Nutr 2018;72(1):105-11 (PMID 28853742)Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 40.Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat 2012;23(2):97-102 (PMID 20524875)Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 41.Weschawalit S et al. Glutathione and its antiaging and antimelanogenic effects. Clin Cosmet Investig Dermatol 2017;10:147-53 (PMID 28490897)Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 42.FDA, Questions and answers on dietary supplements (current as of Aug 27, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 43.Federal Register API searches: "glutathione" (newest); "peptide compounding" and "bulk drug substances" since 2026Tier 1: regulator or registerfederalregister.govread Nov 16, 2026↩
- 44.HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (Wayback copy of Nov 11 2026)Tier 1: regulator or registerhhs.govread Nov 16, 2026↩
- 45.DEA Diversion Control, Controlled Substances – Alphabetical Order (12-Nov-26)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
- 46.FDA warning-letter database, full-text search "glutathione"Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 47.FDA warning letter, Empower Clinic Services LLC dba Empower Pharma, WL 700962 (Apr 2 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 48.FDA warning letter, Staska Pharmaceuticals Inc., WL 699291 (May 5 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 49.FDA warning letter, GenoGenix LLC, WL 718739 (Jan 20 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 50.FDA warning letter, ProRx LLC, WL 723704 (Apr 7 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.
It is not medical advice: a decision about a medication is one to make with a licensed clinician.